The addition of sildenafil to nintedanib provides no improvements in health-related quality of life (HRQoL) in patients with idiopathic pulmonary fibrosis (IPF), according to results of the INSTAGE study presented at the 28th European Respiratory Society International Congress 2018 (ERS 2018).
Digital mindfulness is an acceptable nonpharmacological intervention that can be integrated with existing treatment for patients with asthma to improve quality of life, according to a study from the UK reported at the recent European Respiratory Society (ERS) International Congress 2018.
The anti–interleukin-5 (anti–IL-5) agent reslizumab significantly improves disease control and lung function and reduces the need for oral steroid maintenance therapy in patients with severe eosinophilic asthma, results of a real-life study have shown.
Interstitial lung abnormalities (ILA), a common finding in low-dose chest CT, are associated with a 5.5-fold increase in risk of lung cancer over long-term follow-up, according to a study reported at the European Respiratory Society (ERS) International Congress 2018.
A simple instrument that uses thermistor-based breathing sensors can accurately measure respiratory rate (RR) in children, as well as in adults, holding great potential for diagnosing paediatric pneumonia in low-resource settings, according to a study.
Overnight supplemental oxygen abolished the rise in morning blood pressure (BP) experienced by patients with moderate to severe obstructive sleep apnoea (OSA) following withdrawal of continuous positive airway pressure (CPAP), according to the SOX* trial.
The immediate reduction of cigarette nicotine content results in greater improvements in levels of smoke exposure biomarkers than gradual reduction, though withdrawal symptoms are stronger, according to a recent study.
Patients admitted to the intensive care unit (ICU) with severe influenza have an elevated risk of developing invasive pulmonary aspergillosis, particularly if they are immunocompromised at time of admission, a recent study has shown.
New therapies that specifically target inflammatory pathways or aberrant physiology in severe asthma offer substantial opportunities for effective treatment. Some of these therapies are available under specialist referral, and others are available in the context of clinical trials.